Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia
NCT03332173Phase 2Completed
- Sponsor
- BeiGene
- Start
- Aug 2017
- Primary completion
- May 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in Waldenström's macroglobulinemia (WM), sponsored by BeiGene. Started Aug 2017; status: completed.
02
Drugs
zanubrutinib
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT03332173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332173.